Sanofi breaks ground on new insulin manufacturing facility in Frankfurt

Bitget2026/10/19 10:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sanofi broke ground on a new insulin manufacturing facility at its BioCampus in Frankfurt, Germany.
Full production of insulin active pharmaceutical ingredients is planned for 2032, subject to licensing.
The 36,000-square-meter facility will use advanced automation, digital technologies and artificial intelligence to support long-term global insulin supply.
European Commission clearance in September 2026 allows public support from Germany’s federal government, Hesse and Frankfurt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190630OMX_____CNEWS_EN_GNW1001278634_en) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sanofi breaks ground on new insulin manufacturing facility in Frankfurt

You may also like

Crypto prices